ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to 16.3%

Operating margin was 16.3% in Q1 FY2026, up 3.0 pp from a year earlier. On a trailing-twelve-month basis it was 13.4%, up 12.4 pp year over year. Over 3 fiscal years it widened by 20.3 pp.

Context

  • Operating margin widened in 2 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 6 analysts of 24.2% for the fiscal year ending Dec 2026, up from 9.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
16.3%-3.2 pp QoQ
Last fiscal yearDec 2025
9.2%+9.1 pp YoY
LTMMar 2026
13.4%+12.4 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+3.0 pp+15.5 pp+12.5 pp
1 year+9.1 pp+15.0 pp+5.9 pp
3 years+20.3 pp+15.0 pp-5.4 pp
5 years+14.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
9.2%
Year-over-year change
+9.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How ANIP compares with its peers on the latest reported figures

  • ANIP's LTM Mar 2026 operating margin of 13.4% is the 4th highest of the 11 companies compared; the peer median is 11.0%.
  • Its year-over-year change of +12.4 pp is the 2nd highest of 10, against a peer median of +5.2 pp.
  • Over three fiscal years its change of +20.3 pp compares with a peer median of +13.9 pp.
ANIP Competitors Peer median
Operating Margin for ANIP and competitors
Company Period LTM level YoY 3-year change
BHCBausch Health Companies Inc.LTM Jun 202625.4% +9.0 pp+15.7 pp
COLLCollegium Pharmaceutical, Inc.LTM Mar 202623.8% +2.5 pp+16.8 pp
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 202616.2% -10.5 pp-2.0 pp
ANIPANI Pharmaceuticals, Inc.LTM Mar 202613.4% +12.4 pp+20.3 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202612.9% -0.3 pp+18.3 pp
TEVATeva Pharmaceutical Industries LimitedLTM Jun 202611.5% +6.1 pp+27.2 pp
HROWHarrow Health, Inc.LTM Mar 202610.5% +8.3 pp+12.0 pp
RDYDr. Reddy's Laboratories LimitedLTM Sep 20268.9% -11.9 pp-9.4 pp
LFCRLifecore Biomedical, Inc.LTM Mar 2026-0.1% —-2.8 pp
VTRSViatris Inc.LTM Jun 2026-0.6% +17.8 pp-28.6 pp
EOLSEvolus, Inc.LTM Mar 2026-9.6% +5.2 pp+31.3 pp
Peer median (excluding ANIP) 11.0%+5.2 pp+13.9 pp

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue216.14M316.39M486.82M614.38M883.37M
Cost of Revenue100.61M138.79M181.51M250.21M432.73M
Gross Profit115.53M177.6M305.3M364.17M450.64M
Gross Margin53.5%56.1%62.7%59.3%51.0%
Research & Development11.37M22.32M34.29M44.58M51.66M
Selling, General & Admin84.29M124.04M161.7M249.64M317.75M
Operating Expenses155.32M212.88M258.33M363.58M369.41M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
EBITDA3.12M25.04M106.6M63.12M207.27M
EBITDA Margin1.4%7.9%21.9%10.3%23.5%
Operating Income(39.79M)(35.28M)46.97M584K81.23M
Operating Margin-18.4%-11.2%9.6%0.1%9.2%
Interest Income00000
Interest Expense11.92M28.05M26.94M17.6M20.06M
Other Income / Expenses(16.27M)(27.38M)(27.1M)(22.8M)14.56M
Income Before Tax(56.06M)(62.67M)19.87M(22.21M)95.79M
Pre-Tax Margin-25.9%-19.8%4.1%-3.6%10.8%
Income Tax Expense(13.46M)(14.77M)1.09M(3.69M)17.45M
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Net Margin-19.7%-15.1%3.9%-3.0%8.9%
EPS (Basic)(3.40)(3.05)0.95(1.04)3.50
EPS (Diluted)(3.40)(3.05)0.94(1.04)3.32
Weighted Avg Shares12.6M16.26M18M19.32M20.05M
Weighted Avg Shares (Diluted)12.6M16.26M18.19M19.32M21.23M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.